Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica has filed a new drug submission for alitretinoin with the Therapeutic Products Directorate of Health Canada.
Subscribe to our email newsletter
This submission supports the proposed use of oral alitretinoin in severe refractory chronic hand eczema.
Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema have also been filed in Switzerland and in several EU member states.